Pharmafile Logo
Pharmafocus logo
Advanced Search

semaglutide

Showing 10 posts of 10 posts found.

heartbeat

Novo Nordisk’s Wegovy reduces risk of cardiovascular events

August 9, 2023
Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …

News
lilly_entrance_web

Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

June 28, 2021
Sales and Marketing Eli Lilly, semaglutide, type 2 diabetes

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C and body weight reductions compared …

News

Novo’s oral semaglutide tops Jardiance and Victoza in two type 2 diabetes trials

June 10, 2019
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has taken the opportunity at the American Diabetes Association (ADA) 79th Scientific Sessions to pull back the curtain …

News
novo_nordisk_flag

Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3

November 26, 2018
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide

Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …

News
novo_nordisk_flag

Novo’s semaglutide hits the mark in Phase 3 type 2 diabetes study

August 21, 2018
Manufacturing and Production, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of …

News

Novo’s oral semaglutide beats Victoza and Januvia in diabetes

June 21, 2018
Research and Development Januvia, MSD, Novo Nordisk, Victoza, pharma, semaglutide

Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue …

News

Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial

February 23, 2018
Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …

News

Novo’s diabetes treatment semaglutide gets unanimous FDA backing

October 19, 2017
Sales and Marketing Novo Nordisk, diabetes, semaglutide

Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one …

News
novo_corp_hq2

Novo Nordisk’s diabetes drug “significantly reduced’ cardiovascular risk

September 16, 2016
Medical Communications Novo Nordisk, diabetes, semaglutide

Novo Nordisk has announced that its diabetes drug semaglutide “significantly reduced” the risk of major cardiovascular events at the 52nd …

News

Novo Nordisk pushes forward with new diabetes drug trial

July 13, 2015
Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes

Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023